pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Innovent Biologics Inc

updated 3mo ago

Innovent Biologics, Inc. is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu.

Website ↗
community read0 votes

🐶 often sniffed alongside

top 3
  • tagNASH3 co-mentions · 1 sources
  • tagEndocrinology & Metabolism1 co-mentions · 1 sources
  • drugmazdutide1 co-mentions · 1 sources
pipeline
5
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 1: 2Phase 2: 2Unknown: 1
2Phase 12Phase 21Unknown
Phase 2
IBI-363
Metastatic Melanoma
Phase 2
sintilimab
Angiosarcoma
Programmed cell death protein 1
Phase 1
IBI-3020
Colon Cancer
Phase 1
IBI-3032
Obesity
drug
mazdutide

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Innovent Biologics Inc jobs →

News

  • J&J bets $2.2B on Ollin’s vision loss drug
    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
    biopharma_dive · 7h ago
  • J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
    Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setba…
    biospace · 9h ago
  • J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
    Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.
    fiercebiotech · 15h ago
  • Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
    For executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…
    fiercebiotech · 9d ago
  • At ASH, drugmakers to showcase early data for three-pronged cancer therapies
    J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.
    biopharma_dive · 11d ago
  • ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
    Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) demonstrating overall survival of 10.2 months.
    fiercebiotech · 24d ago
  • Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
    Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can breathe a measured sigh of relief.
    fiercebiotech · 25d ago
  • Lilly’s latest China drug deal; Immunovant’s setback in lupus
    Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…
    biopharma_dive · 1mo ago
  • China poses increasing security risk as US biotech innovation edge erodes
    The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winn…
    biospace · 2mo ago
  • RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
    Plus news about Avere Therapeutics, Novo Nordisk, Sobi, Innate Pharma, Oculis, Innovent Biologics and Daiichi Sankyo. 🌏 BeOne gets rights to RevMed drugs in 'select Asian markets': The deal includ…
    endpoints · 3mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Oncology3Colorectal Cancer1NSCLC1Obesity1
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?